Cogentix Medical, Inc. / Laborie Medical Technologies Canada ULC Merger Litigation
TORONTO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- On March 11, 2018, Cogentix Medical, Inc. (“Cogentix”) and certain affiliates of Laborie Medical Technologies Canada ULC (“Laborie”), LM US Parent, Inc. (“Parent”) and Camden Merger Sub, Inc. (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Cogentix would become a wholly-owned subsidiary of Parent (the “Merger”). Pursuant to the terms of the Merger Agreement, Merger Sub commenced a tender offer (the “Tender Offer”) to purchase all of the outstanding shares of Cogentix’s common stock. On March 26, 2018, in connection with the Tender Offer, Cogentix filed a Schedule 14D-9 Solicitation/Recommendation Statement with the United States Securities and Exchange Commission (the “SEC”).
Subsequent to the commencement of the Tender Offer and the filing of the Schedule 14D-9, Cogentix’s directors, Laborie, Parent, and Merger Sub were named as defendants in a purported class action lawsuit related to the proposed Merger that was filed in the Delaware Court of Chancery (Franchi v. Uri Geiger, et al., C.A. No. 2018-0258-AGB). The lawsuit generally alleged that Cogentix’s directors breached their fiduciary duties to Cogentix’s stockholders, and that Laborie, Parent, and Merger Sub aided and abetted the alleged breaches. The plaintiff also filed a motion to expedite proceedings and a preliminary injunction motion to enjoin the close of the Tender Offer and proposed Merger. After defendants produced certain confidential documents to plaintiff and Cogentix filed with the SEC an amendment to the Schedule 14D-9 on April 10, 2018 that contained additional disclosures relating to the Merger (the “Supplemental Disclosures”), plaintiff determined that the claims asserted in the complaint were mooted and plaintiff withdrew the pending expedition and injunction motions.
The Tender Offer expired on April 20, 2018, and the Merger was consummated on April 23, 2018, whereby Cogentix became a wholly-owned subsidiary of Parent and Cogentix’s common stock was delisted from the Nasdaq Capital Market. Subsequent to the closing of the Merger, plaintiff informed defendants that plaintiff had determined to dismiss the action with prejudice as to himself and without prejudice as to Cogentix’s other stockholders, and that plaintiff would seek an award of attorneys’ fees and expenses in connection with the Supplemental Disclosures. After plaintiff informed defendants of his determination to dismiss the action, the parties engaged in discussions regarding a potential resolution of plaintiff’s anticipated fee and expense application, and ultimately agreed to a payment made directly by Laborie to plaintiff’s counsel in the amount of $137,500.
The Delaware Court of Chancery subsequently entered an order that required the parties to provide notice of the dismissal of the action on mootness grounds and the agreed payment of plaintiff’s counsel’s fees and expenses to allow Cogentix and/or Laborie stockholders the opportunity to object. Pursuant to the Court’s order, following the expiration of a thirty-day notice period, the parties will inform the Court regarding any responses to the notice and, if appropriate, submit a proposed order providing that the action and the claims asserted therein are dismissed with prejudice as to the named plaintiff only, and without prejudice as to members of the putative class of Cogentix stockholders. With the exception of considering any potential objections to the payment of plaintiff’s counsel’s fees and expenses, the Court of Chancery has not been asked to review, and will pass no judgment on, the payment of a fee or its reasonableness.
Any objections to the dismissal of the action on mootness grounds and the proposed payment of plaintiff’s counsel’s fees and expenses should be sent within thirty days of the posting of this notice to counsel for plaintiff, Brian D. Long, at bdl@rl- legal.com or 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, and counsel for defendants, Steven L. Caponi, at email@example.com or 600 N. King Street, Suite 901, Wilmington, DE 19801.
For Further Information:
LABORIE Medical Technologies
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration23.8.2019 22:01:00 CEST | Press release
Foster City, Calif. and Mechelen, Belgium; 23 August 2019; 22.01 CET; regulated information – Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced the closing of the global research and development collaboration agreement signed on 14 July 2019. This agreement has received clearance from the U.S. Federal Trade Commission under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and merger control approval from the Austrian Federal Competition Authority. Under the terms of the agreement, the closing of this transaction triggers an upfront license fee payment of $3.95 billion by Gilead to Galapagos. In addition, Gilead has made an equity investment in Galapagos of approximately $1.1 billion (or approximately €960 million) by subscribing for new shares at a price of €140.59 per share, including issuance premium. As a result, Gilead now owns 13,589,686 ordinary shares of Galapagos, representing approximately 22 percent of the currently outsta
EVS Broadcast Equipment strikes major deal with NEP to upgrade their US production activities23.8.2019 18:00:00 CEST | Press release
Publication on August 23 2019, 06:00 P.M. CET Regulated information – Privileged information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS STRIKES MAJOR DEAL WITH NEP TO UPGRADE THEIR US PRODUCTION ACTIVITIES EVS Broadcast Equipment, the leading provider of live production solutions, today announces that NEP is investing over $8m to deploy the next generation EVS live video production server as part of their US inventory. Liège, Belgium, August 23, 2019 EVS, the leading provider of live production solutions, has been selected by NEP, an international production company serving live broadcasting throughout the world, to deliver a major upgrade and upscale of their production facilities. The deal represents the acquisition of EVS’ XT-VIA next-generation live production servers, as well as the deployment of LSM replay controllers, IPDirector content management solutions and other infrastructure systems. All new systems will be installe
Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 201923.8.2019 17:35:00 CEST | Press release
Allschwil, Switzerland – August 23, 2019 Idorsia Ltd (SIX: IDIA) today announced that data from Phase 2 studies with aprocitentan, a new dual endothelin receptor antagonist, and selatogrel, a highly-selective P2Y12 receptor antagonist, will be shared during the European Society of Cardiology (ESC) Congress 2019 in Paris, France. Idorsia’s aprocitentan An oral presentation entitled "Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension", will be part of the "Drug treatment in hypertension - New insights" session with a focused discussion with the lead author, Dr Parisa Danaietash from Idorsia, at 09:54 on August 31, 2019. The abstract can be found online. Idorsia’s selatogrel An oral presentation entitled "Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients", will be part of th
Millicom - H1 2019 Consolidated Financial Statements23.8.2019 16:53:00 CEST | Press release
Millicom’s H1 2019 Consolidated Financial Statements Luxembourg, August 23, 2019— Millicom, a leading provider of cable and mobile services operating under the TIGO brand in Latin America, has published its H1 2019 consolidated financial statements. Contents include: • Management Report • Responsibility Statement • Review Report of the Independent Auditors • Unaudited Interim Condensed Consolidated Financial Statements -END- For further information, please contact Press: Vivian Kobeh, Corporate Communications Director +1 786-628-5300 firstname.lastname@example.org Investors: Michel Morin, VP Investor Relations +1 786-628-5270 email@example.com Sarah Inmon, Investor Relations Manager +1-786-628-5303 firstname.lastname@example.org About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of cable and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around T
Banks net position in the Riksbank23.8.2019 16:42:00 CEST | Press release
AUG 23, 2019 SEK MILLION LENDING BORROWING 265
Conditions for Riksbank Bid Procedures Sek Bonds23.8.2019 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2019-08-29 Maturity date Loan ISIN code Coupon Volume, SEK million 2025-05-12 1058 SE0005676608 2.50 % 500 +/- 250 2039-03-30 1053 SE0002829192 3.50 % 500 +/- 250 Settlement date 2019-09-02 Bids have to be entered by 10.00 on AUG 29, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1058 and 500 SEK million in issue SGB 1053 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON AUG 29, 2019. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se